Pentoxifylline may protect kidney and heart health in diabetic nephropathy
Key Takeaway:
In adults with type 2 diabetes and advanced diabetic nephropathy, pentoxifylline lowered albuminuria and helped preserve kidney function and left ventricular mass compared with placebo.
Study at a Glance
What was studied
Pentoxifylline versus placebo in diabetic nephropathy with kidney and cardiac markers.
Study Type
Randomized Controlled Trials (RCTs)
duration
Medium-Term (3–12 mo)
Intervention
Pentoxifylline
Outcomes
Albuminuria, Estimated glomerular filtration rate, Left ventricular mass index, NT-proBNP, Serious adverse events incidence
Funding
Non-Industry Sponsored
Save this study and add notes to your research library.
Main Effects
↓ Albuminuria at 6 and 12 months compared with placebo
↑ Estimated glomerular filtration rate preservation at 12 months compared with placebo
↓ Left ventricular mass index worsening at 6 and 12 months compared with placebo
Evidence Summary
| Intervention | Outcome | Measured Change | Study Effect |
|---|---|---|---|
 Pentoxifylline (Medications) |  Albuminuria (Clinical Outcomes) | Decrease | Strong |
Pentoxifylline (Medications) | Estimated glomerular filtration rate (Clinical Outcomes) | Increase | Mixed |
Pentoxifylline (Medications) |  Left ventricular mass index (Metabolic Health) | Decrease | Mixed |
Pentoxifylline (Medications) | NT-proBNP (Metabolic Health) | Uncertain | Limited |
Unlock Full Evidence Analysis
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Evidence Suggest
- Microalbuminuria increased in placebo but decreased in the pentoxifylline group at 6 and 12 months.
- Estimated GFR declined more in placebo than with pentoxifylline, with the 12-month difference favoring pentoxifylline.
- Left ventricular mass index increased in placebo but stayed roughly stable in the pentoxifylline group.
Who this applies to
Adults with type 2 diabetes.
Keep in Mind
This was an exploratory trial using surrogate outcomes.
Between the Lines
- Per-protocol analysis may be less protective against bias than intention-to-treat analysis.
- Final analyzed sample was small, with 93 participants.
- Outcomes were surrogate kidney and cardiac markers, not dialysis, major cardiovascular events, or mortality.
- The trial was conducted in one health system, which may limit generalizability.
Unlock Full Analysis
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Journal Reference
Short- and Middle-Term Nephroprotective and Cardioprotective Effects of Pentoxifylline in Patients with Diabetic Nephropathy: A Randomized Controlled Trial. Med Sci (Basel). 2026;14(1):26. doi:10.3390/medsci14010026
Connected Evidence
Discover how this study fits into the broader diabetes evidence landscape.
This study contributes to evidence on Pentoxifylline and Kidney Function.
Related evidence relationships
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention–outcome relationships.
Included in these evidence collections
Curated evidence collections and hubs this study is part of.
Explore more in the evidence archive
Jump to pre-filtered views in the evidence archive.
Questions this evidence helps answer
Key clinical and research questions this study contributes to.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.